A CASE SERIES OF PATIENTS WITH CUTANEOUS T‐CELL LYMPHOMA TREATED WITH COMBINATION MOGAMULIZUMAB AND OTHER THERAPIES AFTER SINGLE AGENT MOGAMULIZUMAB

Introduction: Mogamulizumab (moga) is an anti-CCR4, monoclonal antibody approved as monotherapy for the treatment of relapsed/refractory mycosis fungoides (MF) and Sezary syndrome (SS). Combination therapies are frequently utilized in cutaneous T-cell lymphoma (CTCL), part due to variation response across blood, nodal, skin compartments. Little known about moga combination with other therapies. Methods: We conducted a single institution retrospective analysis MF/SS patients who were treated systemic therapies, including peginterferon alpha-2a (IFNα), bexarotene, extracorporeal photopheresis (ECP), oral methotrexate between March 2019 2023. Baseline characteristics clinical outcomes recorded summarized. Responses assessed by Olsen staging criteria (Olsen et al., 2022). Results: identified 9 therapy at our (Table 1). Six 7 transitioned from mono progressive disease or stable uncontrolled symptom burden. Median time next was 157.5 days (range 42-330) monotherapy. The best observed 8 agent classified as: 4 (50%) partial responses (PR), 3 (37.5%) (SD), 1 (12.5%) (PD). total different combinations (6 2 skin-directed), which included IFNα (n = 4), bexarotene (2), ECP electron beam radiation (TSEB) narrow band ultraviolet-B (NBUVB) (1), + (1). Multiple received more than one treatment. Among median 137 24-224 days) out 6 having ongoing +/- ECP. patient PR on prior His involvement improved T4 T1 but significant blood persisted (B2). He continues now 846 later. Conclusions: has patients, global complete rare seen blood. In series, addition provided benefits SD PD moga. One achieved lengthy despite persistent peripheral samples. speculate may augment antibody-dependent cellular cytotoxicity thereby improving efficacy Additionally, combinatorial approaches improve skin, nodes, viscera where lower Further investigations needed. Keywords: Therapies, Cutaneous non-Hodgkin No conflicts interests pertinent abstract.